Categories Earnings, Health Care

Amicus Therapeutics (FOLD): FY 2019 Earnings Snapshot

— Biotechnology company Amicus Therapeutics (NASDAQ: FOLD) reported a net loss of $356.4 million or $1.48 per share for fiscal 2019, compared to a loss of $349 million or $1.88 per share in the preceding year.

— Total revenues nearly doubled to $182.2 billion in 2019 from $91.25 million in 2018

— Adjusted operating expenses were $464.3 million in 2019, up 14% compared to fiscal 2018

— Expects revenues of Galafold, a therapy for Fabry disease in adults, to be in the range of $250 million to $260 million in fiscal 2020

— Estimates full-year operating expense to be in the range of $410 million to $420 million, which represents an increase from last year

— On track to continue ongoing operations well into 2022, making use of the current cash position

— Looks to complete Pompe Phase-3 PROPEL study, enroll pediatric studies and advance manufacturing to support 2021 BLA and MAA

Get access to timely and accurate in verbatim transcripts that are published within hours of the event

Most Popular

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Target (TGT): A look at some of the challenges faced by the retailer in 3Q24

Shares of Target Corporation (NYSE: TGT) stayed green on Thursday, recovering from the stumble it took a day ago after delivering disappointing results for the third quarter of 2024 and

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top